vTv Therapeutics is a clinical-stage biopharmaceutical company developing orally administered small molecule drug candidates to fill significant unmet medical needs in Alzheimer's disease (AD), diabetes and inflammatory disorders.
3980 Premier Drive, Suite 380
4160 Mendenhall Oaks Parkway, Suite 105
Employment range in NC
Primary site activity
All company activities
Potential end market(s)
Products under development
The company's leading clinical candidates are TTP399 as an adjunct therapy to insulin for people with type 1 diabetes and azeliragon for the potential treatment of mild-AD in patients with type 2 diabetes.